Premium
THE USE OF SULTHIAME IN MYOCLONIC EPILEPSY OF CHILDHOOD AND ADOLESCENCE
Author(s) -
Lerman Pinchas,
Nussbaum Eliezer
Publication year - 1975
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1975.tb01382.x
Subject(s) - juvenile myoclonic epilepsy , medicine , myoclonic epilepsy , epilepsy , pediatrics , dravet syndrome , psychomotor learning , psychiatry , cognition
Sulthiame has been used by most investigators in psychomotor seizures, other focal seizures and grand‐mal, usually in conjunction with other anti‐convulsants. Reports on its use in myoclonic epilepsy and as a sole anti‐convulsant are few and inconclusive. The present report presents the results of a study carried out on the use of sulthiame in 54 cases of myoclonic epilepsies originating in infancy, childhood and adolescence. The different types of myoclonic epilepsy are defined. An illustrative case report is included. Results indicated that sulthiame is the drug of choice, often as the sole anti‐convulsive agent, in cases of “juvenile myoclonic epilepsy”. In the myoclonic encephalopathies of childhood (the so‐called “minor motor epilepsy” or Lennox‐Gastaut syndrome), which are notoriously refractory to therapy, sulthiame appears to be an efficacious adjunct to currently‐used agents, including benzodiazepines, succinimides, dipropyl acetate, steroids and a ketogenic diet.